Archus cuts staff for cash stability
This article was originally published in Clinica
Executive Summary
Spinal implant specialist Archus Orthopedics has cut staff in order to conserve its cash reserves, says business and technology website Xconomy Seattle. Archus, which had a workforce of 45 people, has also had to reduce its business operations in order to sustain its capital. According to Xconomy Seattle, the company’s CEO Jim Fitzsimmons said that the pre-revenue firm had been affected by the “extremely challenging financing market” but is looking at options to maximise shareholder value. The Redmond, Washington-based company is currently developing its Total Facet Arthroplasty System (TFAS), which is designed to restore normal motion and provide stabilisation of spinal segments.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals